#semaglutide

As of 2026, two FDA-approved oral GLP-1 pills exist for weight loss: Foundayo (orforglipron, 12.4% weight loss, $149/mo self-pay via LillyDirect, no fasting needed, approved April 1) and the Wegovy pill (semaglutide 25mg, 16.6% weight loss, $1,349/mo list price, requires 30-min fast before dosing, approved December 2025). Rybelsus is oral semaglutide but approved for type 2 diabetes only — not weight loss.

Updated May 2026: FDA proposed on April 30 to permanently remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — effectively closing the door on large-scale compounding if finalized. 503A enforcement began April 22, 2025. 503B enforcement May 22, 2025. 3-4 million patients affected. Legal alternatives: compounded tirzepatide ($149-299/mo, medical-necessity only), Wegovy $349/mo via NovoCare, or Foundayo $649/mo.

Verified May 8, 2026: On April 30, FDA proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulk list — forever, not just during shortage enforcement. Public comment closes June 29, 2026. If finalized, no 503B pharmacy could bulk-compound these GLP-1 drugs in the future, even if a new shortage is declared. 503A patient-specific compounding under medical-necessity remains unaffected.

Updated May 2026: 5 next-gen obesity drugs in Phase 3. Retatrutide (Lilly) 28.7% weight loss. CagriSema (Novo): REDEFINE-1 22.7% (obesity), REDEFINE-2 15.7% (T2D), PDUFA expected October 2026. MariTide (Amgen, monthly), survodutide, Foundayo approved April 2026. FDA approvals 2026-2028.

FDA-approved GLP-1 receptor agonists for weight loss — 2026 guide. Eligibility: BMI 30+ (or 27+ with comorbidity). Semaglutide produces 14.9% weight loss (STEP-1), tirzepatide 20.9% (SURMOUNT-1). Cost: $25-$349/mo via telehealth. Complete 5-step prescription process with verified provider pricing. Options: Foundayo (orforglipron), oral Wegovy, Zepbound, and injectable semaglutide.

Verified April 2026: Brand-name Wegovy is $349/mo via NovoCare, Zepbound starts at $299/mo via LillyDirect. Compounded semaglutide is banned since Feb 2025; compounded tirzepatide remains legal at $149-299/mo under narrow medical-necessity rules. Full legal + safety comparison.

Verified April 2026: GLP-1 patients lose 2-5 pounds in their first month. Appetite suppression starts week 1-2. Nausea peaks at week 4 dose escalation. 98.1% of GI side effects are mild-to-moderate per STEP-1 and SURMOUNT-1 trials. Complete week-by-week timeline with dosing schedule.

Verified April 2026: Zepbound (tirzepatide) produces 20.9% body weight loss vs Wegovy's (semaglutide) 14.9% per the SURMOUNT-1 and STEP-1 trials. Wegovy self-pay: $349/mo (NovoCare). Zepbound self-pay: $299-$449/mo (LillyDirect). Both $25/mo with commercial insurance + savings card.

Verified April 2026: Ozempic and Wegovy are both semaglutide from Novo Nordisk. Ozempic ($1,028/mo list) is approved for type 2 diabetes at max 2mg. Wegovy ($1,349/mo list) is approved for weight loss at max 2.4mg (or 7.2mg HD). Both drop to $349/mo self-pay via NovoCare.

Verified April 2026: Oral Wegovy (25mg daily pill) produces 16.6% weight loss per the OASIS trial vs 14.9% for injectable Wegovy (2.4mg weekly) per STEP-1. Pill costs $1,349/mo list vs $349/mo self-pay for the injection through NovoCare. Full head-to-head comparison.

Verified April 2026: Tirzepatide produces 20.2% weight loss vs semaglutide's 13.7% in the head-to-head SURMOUNT-5 trial (NEJM). Tirzepatide activates GLP-1 + GIP dual receptors; semaglutide activates GLP-1 only. Tirzepatide costs $449/mo vs $349/mo self-pay. Full comparison.

Verified April 2026: The 7 worst foods on Ozempic, Wegovy, Zepbound — fried food, sugary drinks, red meat portions, raw cruciferous veg, carbonated beverages, alcohol, high-fiber bars. GLP-1s slow gastric emptying 25-40%, triggering nausea in 44% of patients. Full list with alternatives.

Verified April 2026: 44% of Wegovy patients report nausea, 30% diarrhea, 24% vomiting in STEP-1 trial. Only 7% discontinued for side effects. Tirzepatide (Zepbound) is more tolerable: 24-33% nausea, 7-13% vomiting per SURMOUNT-1. Full management guide with red flags.

Verified April 11, 2026: The FDA issued 14 new warning letters to GLP-1 compounders between March 12 and April 8, 2026 — the largest enforcement wave since the semaglutide compounding ban. Full list of affected pharmacies, what they violated, and what to do if you were a patient.

Clinical trials show 15–17% body weight loss with semaglutide over 68 weeks. Here's what to expect month by month, backed by data from the STEP trials.

GLP-1 patches sold online don't contain semaglutide or tirzepatide — they're herbal supplements. Here's what the science says and what actually works.